The effect of Oren-gedoku-to on experimental colitis in rats

被引:21
作者
Zhou, H [1 ]
Mineshita, S [1 ]
机构
[1] Tokyo Med & Dent Univ, Med Res Inst, Div Social Med, Dept Prevent Med,Bunkyo Ku, Tokyo 113, Japan
关键词
D O I
10.1211/0022357991773401
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
In Japan and China, Oren-gedoku-to (a complex mixture of ingredients derived from plants) has been used as a herbal medicine in the treatment of inflammatory and ulcerative diseases. In other countries salicylazosulfapyridine has been used to treat inflammatory bowel disease. In this study, we have compared the effect of Oren-gedoku-to with salicylazosulfapyridine on trinitrobenzene-sulphonic acid-induced colonic damage in rats, a model representative of ulcerative colitis and Crohn's disease in man. Oren-gedoku-to was administered orally for one or two weeks over a range of doses. Tissue damage scores, body weight, spleen weight, colon wet weight and colon wall thickness were measured, and colonic tissue levels of interleukin-8 (IL-8), leukotriene B-4 (LTB4), prostaglandin E-2 (PGE(2)), and myeloperoxidase activity were examined. The results indicated that Oren-gedoku-to was effective in the treatment of inflammatory bowel disease in the rat model. Histological observation showed a quicker healing process of the lesions, and a reduction of inflammatory cell infiltration following administration of Oren-gedoku-to. The precise mechanism of action for (Oren-gedoku-to is still unclear; however, the reduction of IL-8, LTB4, and PGE2 observed suggests that the mechanism may be different from salicylazosulfapyridine (which has no effect on IL-8). There may be a potential benefit in offering combination therapy for the treatment of inflammatory bowel disease.
引用
收藏
页码:1065 / 1074
页数:10
相关论文
共 44 条
[1]
NEUTROPHIL-ACTIVATING PEPTIDE-1 INTERLEUKIN-8, A NOVEL CYTOKINE THAT ACTIVATES NEUTROPHILS [J].
BAGGIOLINI, M ;
WALZ, A ;
KUNKEL, SL .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04) :1045-1049
[2]
Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease [J].
Daig, R ;
Andus, T ;
Aschenbrenner, E ;
Falk, W ;
Scholmerich, J ;
Gross, V .
GUT, 1996, 38 (02) :216-222
[3]
De Gendt CM, 1998, J RHEUMATOL, V25, P536
[4]
ROLE OF PLATELET-ACTIVATING FACTOR IN ULCERATIVE-COLITIS - ENHANCED PRODUCTION DURING ACTIVE DISEASE AND INHIBITION BY SULFASALAZINE AND PREDNISOLONE [J].
ELIAKIM, R ;
KARMELI, F ;
RAZIN, E ;
RACHMILEWITZ, D .
GASTROENTEROLOGY, 1988, 95 (05) :1167-1172
[5]
LEUKOTRIENE-B, A POTENT CHEMOKINETIC AND AGGREGATING SUBSTANCE RELEASED FROM POLYMORPHONUCLEAR LEUKOCYTES [J].
FORDHUTCHINSON, AW ;
BRAY, MA ;
DOIG, MV ;
SHIPLEY, ME ;
SMITH, MJH .
NATURE, 1980, 286 (5770) :264-265
[6]
STUDIES ON ATTENUATION OF POSTISCHEMIC BRAIN INJURY BY KAMPO MEDICINES-INHIBITORY EFFECTS OF FREE-RADICAL PRODUCTION .2. [J].
FUSHITANI, S ;
MINAKUCHI, K ;
TSUCHIYA, K ;
TAKASUGI, M ;
MURAKAMI, K .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1995, 115 (08) :611-617
[7]
ROLE OF CYTOKINE-INDUCED NEUTROPHIL CHEMOATTRACTANT, A MEMBER OF THE INTERLEUKIN-8 FAMILY, IN RAT EXPERIMENTAL COLITIS [J].
HARADA, K ;
TOYONAGA, A ;
MITSUYAMA, K ;
SASAKI, E ;
TANIKAWA, K .
DIGESTION, 1994, 55 (03) :179-184
[8]
HOSHINO E, 1994, JPN J GASTROENTEROL, V91, P355
[9]
Ina K, 1997, AM J GASTROENTEROL, V92, P1342
[10]
Izutani R, 1995, Inflamm Bowel Dis, V1, P37, DOI 10.1002/ibd.3780010106